Results for tag: "Belinostat"

Belinostat is a histone deacetylase inhibitor (HDACi) used to treat certain types of leukemia. It is approved by the US Food and Drug Administration (FDA) for the treatment of peripheral T-cell lymphoma (PTCL) in adults who have received at least one prior therapy. Belinostat works by blocking the action of an enzyme called histone deacetylase, which is involved in the regulation of gene expression. This helps to reduce the growth of cancer cells. Belinostat is used in combination with other drugs to treat certain types of leukemia, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and acute lymphoblastic leukemia (ALL). It is also used to treat certain types of non-Hodgkin lymphoma (NHL). Belinostat is marketed by Spectrum Pharmaceuticals, Inc. and is available in the United States, Europe, and other countries. Other companies involved in the market include Eisai Co., Ltd., Merck KGaA, and Teva Pharmaceutical Industries Ltd. Show Less Read more